| Non-Myeloablative Allogeneic Transplantation 2002 Edition Contributor(s): Bashey, Asad (Editor), Ball, Edward D. (Editor) |
|
 |
ISBN: 0792376463 ISBN-13: 9780792376460 Publisher: Springer OUR PRICE: $104.49 Product Type: Hardcover - Other Formats Published: February 2002 Annotation: Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem cells and lymphocytes. It has the potential to deliver the potent anti-tumor immunotherapy and bone marrow replacement capacity of allogeneic stem cell transplantation to patients with reduced treatment-related morbidity and mortality. It may also enable allogeneic transplantation in patients who would be considered ineligible for conventional transplants because of co-morbidity or advanced age. However, this approach may necessitate more careful monitoring of post-transplant chimerism and malignant disease-status than is usual with conventional allografting. There is also controversy regarding the best preparative regimen and graft-versus-host disease prophylaxis to use. Non-Myeloablative Allogeneic Transplantation will provide both practitioners and academic clinicians with a better understanding of underlying concepts, current methodologies, and results obtained by the pioneering centers for this rapidly evolving field. |
| Additional Information |
| BISAC Categories: - Medical | Oncology - General - Medical | Surgery - Transplant |
| Dewey: 616.994 |
| LCCN: 2001050705 |
| Series: Cancer Treatment and Research |
| Physical Information: 0.7" H x 6.42" W x 9.52" (1.16 lbs) 216 pages |
| Descriptions, Reviews, Etc. |
| Publisher Description: Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem cells and lymphocytes. It has the potential to deliver the potent anti-tumor immunotherapy and bone marrow replacement capacity of allogeneic stem cell transplantation to patients with reduced treatment-related morbidity and mortality. It may also enable allogeneic transplantation in patients who would be considered ineligible for conventional transplants because of co-morbidity or advanced age. However, this approach may necessitate more careful monitoring of post-transplant chimerism and malignant disease-status than is usual with conventional allografting. There is also controversy regarding the best preparative regimen and graft-versus-host disease prophylaxis to use. Non-Myeloablative Allogeneic Transplantation will provide both practitioners and academic clinicians with a better understanding of underlying concepts, current methodologies, and results obtained by the pioneering centers for this rapidly evolving field. |